Rajesh Pahwa, MD
Rajesh Pahwa, M.D., is the Laverne and Joyce Rider Professor of Neurology, chief of the Parkinson's and Movement Disorder Division and director of Parkinson Foundation Center of Excellence at the University of Kansas Medical Center.
Dr. Pahwa received his M.B.B.S. (M.D.) degree at Seth G.S. Medical College, University of Bombay, India. He completed an internship in medicine at Baylor College of Medicine followed by a residency in Neurology at Baylor College of Medicine, Houston, Texas. He then completed a one-year fellowship in movement disorders at the University of Kansas Medical Center. Dr. Pahwa joined the faculty of the Department of Neurology as an instructor in 1992.
Dr. Pahwa was named the inaugural recipient of the Laverne and Joyce Rider Professorship in 2005. This professorship is named for the late Joyce Rider, a longtime Kansas City, Mo., resident, and for her mother, Laverne Stapp Rider, who battled Parkinson's disease for many years. Joyce Rider, who died in 2004, bequeathed financial support for the professorship to the University of Kansas Endowment Association.
Dr. Pahwa is a Diplomate of the American Board of Psychiatry and Neurology.
Additionally, the Parkinson’s Disease and Movement Disorders Clinic at The University of Kansas Health System is under Dr. Pahwa’s direction and offers diagnostic and treatment services for people with Parkinson's disease and related disorders such as progressive supranuclear palsy and multiple system atrophy as well as tremor disorders, primary essential tremor.
Education and Training
- MBBS, Bombay U.
- Other, K.E.M. Hospital, Bombay, India, Parel, Bombay
- Other, Baylor College of Medicine, Houston, TX
- Other, Baylor College of Medicine
- Other, University of Kansas School of Medicine
Licensure, Accreditations & Certifications
- Diplomate, Neurology, American Board of Psychiatry and Neurology
- Kansas Medical License, Kansas Board of Healing Arts
- American Neurological Association, Member, 1999 - Present
- Movement Disorder Society, Member, 1997 - Present
- Parkinson's Study Group, Member, 1997 - Present
- Tremor Research Group, Member, 1997 - Present
- American Academy of Neurology, Member, 1992 - Present
- Kansas City Neurology Neurosurgery Society, Member, 1992 - Present
Dr. Pahwa's research interests are centered around the various aspects of Parkinson's disease and essential tremor. He is currently involved in studies related to medical and surgical forms of therapies for Parkinson's disease and essential tremor.
In addition to publishing more than 250 peer-reviewed articles, chapters and abstracts in leading neurology and movement disorder journals, he has conducted more than 150 clinical trials related to Parkinson's disease and other movement disorders. Dr. Pahwa is the co-editor of "Handbook of Parkinson's Disease," 3rd and 4th editions; "Therapy of Parkinson's Disease," 3rd edition; and "Handbook of Essential Tremor and other Tremor Disorders." He also is co-author of the book "Parkinson's Disease: Questions and Answers," 4th edition.
- Moon S, Song H-J, Sharma VD, Lyons KE, Pahwa R, Akinwuntan AE, Devos H. 2020. Classification of Parkinson's disease and essential tremor based on balance and gait characteristics from wearable motion sensors via machine learning techniques: a data-driven approach. J Neuro, 17
- Olanow, C.., Warren, Factor, Stewart., A., Espay, Alberto., J., Hauser, Robert., A., Shill, Holly., A., Isaacson, Stuart, Pahwa, Rajesh, Leinonen, Mika, Bhargava, Parul, Sciarappa, Ken, Navia, Bradford, Blum, David. 2020. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurology, 19 (2), 135-144
- Pahwa R, Bergquist F, Horne M, Minshall ME. 2020. Objective measurement in Parkinson's disease: a descriptive analysis of Parkinson's symptom scores from a large population of patients across the world using the Personal KinetiGraph. J Clin Mov Disord, 7
- Pahwa R, Isaacson SH. 2020. Pathophysiology, patient burden and recognition of OFF episodes of Parkinson's disease. J Clin Psychiatry, 81 (6)
- Pahwa R, Isaacson SH. 2020. Pharmacology and evidence-based strategies for current and emerging treatments for OFF periods in Parkinson disease. J Clin Psychiatry, 82 (1)
- Pfeiffer RF, Isaacson SH, Pahwa R. 2020. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. Parkinsonism Relat Disord, 76, 63-71
- San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, Tolosa E, Schule B, Langston JW, Brice A, Corvol J-C, Goldwurm S, Klein C, Brockman S, Berg D, Brockmann K, Ferreira JJ, Tazir M, Mellick GD, Sue CM, Hasegawa K, Tan EK, Bressman S, Saunders-Pullman R, Michael J Fox Foundation LRRK2 Cohort Consortium. 2020. Nonsteroidal anti-inflammatory use and LRRK2 Parkinson's disease penetrance. Mov Disord, 35 (10)
- Sharma VB, Lyons KE, Nazzaro JM, Pahwa R. 2020. Does post-operative symptomatic lead edema associated with subthalamic DBS implantation impact long-term clinical outcomes?. J Neurol Sci, 15:410:11647
- Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, Johnson R, Chernick D, Hubble J. 2020. EASE LID 2: a 2-year open-label trial of gocovri (amatadine) extended release for dyskinesia in Parkinson's disease. J Parkinson's Dis, 10 (2), 543-558
- Vitek JL, Jain R, Chen L, Troster AI, Schrock LE, House PA, Giroux ML, Hebb AO, Farris SM, Whiting DM, Leichliter TA, Ostrem JL, San Luciano M, Galifianakis N, Verghagen, Metman L, Sani S, Karl JA, Siddiqui MS, Tatter SB, Ul Haq I, Machado AG, Gostkowski M, Tagliati M, Mamelak AN, Okun MS, Foote KD, Moguel-Cobos G, Ponce FA, Pahwa R, Nazzaro JM, Buetefisch CM, Gross RE, Luca CC, Jagid JR, Revuelta GJ, Takacs I, Pourfar MH, Mogilner AY, Duker AP, Mandybur GT, Rosenow JM, Cooper SE, Park MC, Khandhar SM, Sedrak M, Phibbs FT, Pilitsis JG, Uitti RJ, Starr PA. 2020. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicenter, double-blind, randomised, sham-controlled study. Lancet Neurology, 19 (6), 491-501